Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Johnson and Johnson...

    Johnson and Johnson wins California lawsuit claiming asbestos in talc caused cancer

    Written by Ruby Khatun Khatun Published On 2017-11-19T10:00:44+05:30  |  Updated On 19 Nov 2017 10:00 AM IST
    Johnson and Johnson wins California lawsuit claiming asbestos in talc caused cancer

    A California jury on Thursday ruled in favor of Johnson and Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company’s talc-based products including J&J’s Baby Powder.


    The Los Angeles Superior Court jury’s verdict came in the first trial centering on claims that J&J’s talc products contained asbestos. J&J is separately battling thousands of cases claiming those products can also cause ovarian cancer.


    The verdict came in a lawsuit by Tina Herford, who said she developed mesothelioma after using J&J talcum powder products that her lawyers claimed contained asbestos.



    Reuters watched the verdict through an online broadcast by Courtroom View Network. The jury also found in favor of talc supplier Imerys Talc.

    J&J in a statement welcomed the verdict. J&J said it believed that setbacks dealt with individuals pursuing ovarian cancer cases had “forced plaintiff attorneys to pivot to yet another baseless theory.”


    “Johnson’s Baby Powder has been around since 1894 and it does not contain asbestos or cause mesothelioma or ovarian cancer,” J&J said.


    Chris Panatier, Herford’s lawyer, in an email cautioned against reading too much into a single verdict.


    “It is a matter of time before juries begin holding them to account,” he said.


    The verdict came as a federal jury, separately, ordered J&J to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.


    A Mesothelioma is a deadly form of cancer closely associated with exposure to asbestos. It affects the delicate tissue that lines body cavities, most often around the lungs, but also in the abdomen and elsewhere.


    Herford’s lawyers contended that internal J&J documents showed the New Jersey-based company for decades was aware of the presence of asbestos in the talc that was used in its products but kept selling them anyway.


    J&J faces lawsuits by around 5,500 plaintiffs nationally asserting talc-related claims, largely based on claims it failed to warn women about the risk of developing ovarian cancer from the products.


    In five trials in Missouri involving ovarian cancer lawsuits, juries found J&J liable four times and awarded the plaintiffs $307 million. In California, a jury awarded a now-deceased woman $417 million.


    But in October, J&J scored major victories when a Missouri appellate court threw out the first verdict there for $72 million and a California judge tossed the $417 million verdicts.


    The case is Herford et al v. AT&T Corp et al, Los Angeles Superior Court, No. BC646315.




    (Reporting by Nate Raymond in Boston; Editing by Jeffrey Benkoe and Tom Brown)



    asbestosbaby powderCalifornia lawsuitcancerJohnson and JohnsonJohnson Baby Powderlawsuitmesotheliomaovarian cancertalcwins
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok